# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

> **NCT05169580** · PHASE1 · COMPLETED · sponsor: **Fulcrum Therapeutics** · enrollment: 45 (actual)

## Conditions studied

- Sickle Cell Disease
- Sickle Cell Anemia

## Interventions

- **DRUG:** Pociredir oral capsule(s)

## Key facts

- **NCT ID:** NCT05169580
- **Lead sponsor:** Fulcrum Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-13
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169580, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05169580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*